Brad Calvin has a broad, multidimensional business background with expertise in healthcare inclusive of diagnostics, devices and life sciences. During his twenty-five-year tenure in the healthcare industry, Calvin has held executive level positions in general management, sales, marketing, business development and international commercial operations. Calvin has consciously developed broad expertise across multiple disciplines and geographies, managing commercialization strategies and business operations on a global scale for companies such as Abbott, Digene and Beckman Coulter. He understands the workings of organizations from small start-ups to large, complex corporations. Calvin excels at turning around under-performing operations and leading start-up businesses, global and regional commercialization strategies and product development in regulated markets.
Dr. Vincent Shankey received his Ph.D. degree in immunology and medical microbiology from the University of Florida School of Medicine (1977), followed by a postdoctoral fellowship in the Department of Pathology at the University of Pennsylvania from 1977 to 1981. Dr. Shankey has used flow and image cytometry in his research for over thirty years, working in clinical flow cytometry for much of that time. From 1987 through 2001, Shankey was director of research for the Urology Department and scientific director of the Clinical Flow Cytometry laboratory at Loyola University Medical Center, Chicago. In 2001, Dr. Shankey was recruited to join the Advanced Technology Center/Systems Research Group at Beckman Coulter. During this period, the focus of his research was the development of novel approaches to measuring signal transduction pathways and their alterations in human disease. Dr. Shankey has over 60 publications focusing on different aspects of cancer cell biology and immunology.
Dr Bryan H. Norman received his Ph.D. in Organic Chemistry at Emory University and was an NIH Postdoctoral Fellow at Penn State University. After three years at Monsanto/Searle, Bryan joined Eli Lilly and Company in 1993, where he led multiple cross functional drug discovery efforts, many of which culminated in clinical candidates for oncology, endocrine and pain indications. In addition to his expertise in medicinal chemistry, Norman has significant cross functional drug discovery expertise in additional disciplines, such as biomarkers, pharmacokinetic/pharmacodynamic (PK/PD) relationships, mechanisms of drug metabolism and toxicology. He has specific expertise in the mechanisms and mitigation strategies to avoid drug-induced liver injury (DILI). The breadth of his background has led to his service on many Due Diligence teams to assess potential in-license opportunities. Bryan retired from Eli Lilly and Company in 2017 and is currently Adjunct Assistant Professor at the Indiana University School of Medicine, where he teaches multiple drug discovery topics. He is a Volume Editor and serves on the Editorial Board of Burger’s Medicinal Chemistry, Drug Discovery and Development, is on the Board of Directors of the Medicinal and Bioorganic Chemistry Foundation and serves on various grant review committees. He has published over 45 papers in peer-reviewed scientific journals, been named an inventor on over 30 U.S. patents and given many invited lectures at scientific conferences and universities.
Dr. David Hedley completed his graduate research studies in tumor immunology, and his medical oncology specialist training at the Royal Marsden Hospital/Institute of Cancer Research, University of London. Hedley was recruited to the Ludwig Institute for Cancer Research, University of Sydney, where he was junior faculty/medical oncology specialist from 1981 to 1989. Since 1990, Dr. Hedley has been a senior scientist/senior staff physician at the Princess Margaret Hospital/Ontario Cancer Institute, Toronto, where he holds the rank of full professor in the Departments of Medicine and Medical Biophysics at the University of Toronto. Hedley’s laboratory focuses on human cancer biology, with particular emphasis on molecular-targeted therapeutics and extensive use of flow cytometry. Dr. Hedley is the author of over 200 scientific papers, and has published extensively on the development of novel flow cytometry techniques to study cancer biology.
Dr. Brad Henke is currently president and principal consultant at Opti-Mol Consulting, which provides medicinal chemistry and preclinical drug discovery guidance for pharmaceutical, biotech, academic, and not-for-profit organizations. Previously, Dr. Henke was a senior director of chemistry at GlaxoSmithKline, where he led medicinal chemistry research in the areas of metabolic and skeletal muscle diseases. Dr. Henke has a Ph.D. in organic chemistry from the University of Illinois and over 23 years of experience in discovery and development of both small molecule and peptide-based therapeutics.
Jim Karkanias, founder of IOTA Engineering, is a seasoned executive of companies from start-ups to multibillion dollar global corporations. Jim’s expertise spans corporate strategy, R&D, resource management and technical infrastructure in the pharmaceutical, life sciences and IT industries. Karkanias led teams in pioneering software developments including creation of a distributed system designed for remote collection of data from physicians prior to distributed system environments and widespread use of the internet as a business tool. Karkanias served at Microsoft® as senior executive in the Health Solutions Group, senior director of applied research and technology, and partner director of information services program management, and at Merck as an executive director. Jim currently serves as an advisor for ImageSleuth and as a board member for COSBI and Washington Biotechnology and Biomedical Association. Karkanias holds 76 patents.
Bernard Munos is Founder of InnoThink, a consultancy focused on translating innovation research into better business models for the pharma industry and its stakeholders, and Senior Fellow, FasterCures (A Center of the Milken Institute), an “action tank” focused on speeding the discovery and development of new therapies for severe diseases. Previously, Munos served at Merck in positions of increasing responsibility for nearly three decades. Bernard is author of ‘The Innovation Chatroom,’ a blog dedicated to biomedical innovation published in Forbes Magazine. Munos is a Member of the Advisory Council and the Cures Acceleration Network Review Boards of the National Center for Advancing Translational Sciences (NIH), and a Member of the Forum on Drug Discovery, Development and Translation, National Academy of Medicine. Munos has been named one of the 25 most influential people in biopharma by FiercePharma.
Dr. David Parkinson received his medical degree from the University of Toronto. Parkinson is a venture partner at New Enterprise Associates. Previously, Dr. Parkinson served as president and CEO of Nodality, and in senior management positions in oncology research and development at Biogen Idec, Amgen and Novartis. Dr. Parkinson has held academic positions at Tufts and the University of Texas MD Anderson Cancer Center, and is the author of over 100 peer-reviewed publications.
Dr. Michael Rafferty is adjunct professor of medicinal chemistry at the University of Kansas School of Pharmacy and a consultant to drug discovery research programs both in industry and academia. Rafferty’s former positions include executive director of discovery technologies at Pfizer, and vice president of nonclinical development activities at Deciphera Pharmaceuticals. Dr. Rafferty is an inventor on 48 issued U.S. patents and co-author on 56 peer-reviewed papers.
Dr. Bartek Rajwa is assistant professor of computational biology at the Bindley Bioscience Center, Purdue University, Indiana. Dr. Rajwa graduated with a Ph.D. degree in biophysics from Jagiellonian University, Kraków, Poland. Since then, he has been conducting research on high-throughput cytometry, high-content imaging, biological pattern recognition, and applications of statistical machine learning in cytomics and phenomics. Rajwa’s research is focused on methods and techniques for the quantitative description of cellular phenotypes using single cell-analysis. Dr. Rajwa has co-authored over 50 peer-reviewed papers and has presented his research at numerous national and international meetings in the fields of cytometry, optical engineering, biomolecular science and applied mathematics. Since 2008, Rajwa has served as a member of the Editorial Board of Cytometry Part A.
Dr. Rob Young recently established his own medicinal chemistry consulting firm, Blue Burgundy, after a long and distinguished career with GSK at their UK R&D headquarters in Stevenage, where he was a Scientific Leader and elected GSK Fellow. Young’s early career charted significant contributions to six development candidates in antivirals (HIV/HBV/Herpes), iNOS and Factor Xa. He then moved to early stage discovery, fulfilling leadership roles in numerous Hit-to-Lead programs, using diverse technologies including HTS, fragments, focused & designed screens and DNA-encoded libraries. Substantive transnational programs also saw him involved with the GSK Diseases of the Developing World group in Spain, encompassing leadership of several Hit-to-Lead programs, plus mentoring and SAB roles. Expertise in Physical Properties and the Property Forecast Index were developed in a productive partnership with Alan Hill spanning may years, which was instrumental in setting new standards in drug discovery with chromatographic methods. He was appointed to numerous GSK cross-disciplinary initiatives and communities including in silico predictive modelling, DMPK, Physical Chemistry, Stability and Safety. Young is author/inventor on 100 publications/ patent applications and an honorary visiting Professor, University of St Andrews. He received his PhD from the University of Oxford and completed his Post Doc at the Ben May Institute, University of Chicago.
Prof. Rogers is Executive Director Cybersecurity Programs, Fellow of the American Academy of Forensic Sciences (AAFS) and Fellow – Center for Education and Research in Information Assurance and Security (CERIAS) at Purdue University. Prof. Rogers is also the Editor-in-Chief of the Journal of Digital Forensics Security & Law (JDFSL), and a member of the Board of Directors of the AAFS. His research interests include applied cyber forensics, psychological digital crime scene analysis, and cyber terrorism.